High-efficacy therapies for relapsing-remitting multiple sclerosis: implications for adherence. An expert opinion from the United Arab Emirates

被引：7

作者：

Inshasi, Jihad Said ^{[1
,2
]}

Almadani, Abubaker ^{[2
,3
]}

Al Fahad, Sarmad ^{[4
]}

Noori, Suzan Ibrahim ^{[5
]}

Alsaadi, Taoufik ^{[6
]}

Shakra, Mustafa ^{[7
]}

Shatila, Ahmed Osman ^{[8
]}

Zein, Tayseer Mohammed ^{[9
]}

Boshra, Amir ^{[10
]}

机构：

[1] Rashid Hosp, MS Sect, Dubai, U Arab Emirates

[2] Dubai Hlth Author DHA, Dubai Med Coll, Dubai, U Arab Emirates

[3] Rashid Hosp, Dubai, U Arab Emirates

[4] Neurospinal Hosp, Baghdad Med Coll, Neurol Dept, Dubai, U Arab Emirates

[5] UHS Univ Hosp Sharjah, Med Coll, Sharjah, U Arab Emirates

[6] Amer Ctr Psychiat & Neurol, Neurol Dept, Dubai, U Arab Emirates

[7] Sheikh Khalifa Med City, Dept Neurol, Abu Dhabi, U Arab Emirates

[8] Mafraq Hosp, Neurol, Abu Dhabi, U Arab Emirates

[9] AlQassami Hosp, Dept Neurol & Neurophysiol, Sharjah, U Arab Emirates

[10] Merck Serono Middle East FZ Ltd, Dubai, U Arab Emirates

来源：

NEURODEGENERATIVE DISEASE MANAGEMENT | 2020年 / 10卷 / 04期

关键词：

disease-modifying therapy; multiple sclerosis; DISEASE-MODIFYING THERAPIES; PLACEBO-CONTROLLED TRIAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; DETERMINE PATIENT PREFERENCES; DISCRETE-CHOICE EXPERIMENT; DOUBLE-BLIND; INTERFERON BETA-1A; CONTROLLED PHASE-3; INTRAMUSCULAR INTERFERON; RETROSPECTIVE ANALYSIS;

D O I：

10.2217/nmt-2020-0016

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The number of disease-modifying treatments (DMDs) for relapsing-remitting multiple sclerosis has increased. DMDs differ not only in their efficacy and safety/tolerability, but also in the treatment burden of, associated with their initiation, route/frequency of administration, maintenance treatment and monitoring. High-efficacy DMDs bring the prospect of improved suppression of relapses and progression of disability, but may have serious safety issues, and burdensome long-term monitoring. Studies of patient preferences in this area have focused on side effects, efficacy and route of administration. Adherence to DMDs is often suboptimal in relapsing-remitting multiple sclerosis and there is a need to understand more about how the complex therapeutic and administration profiles of newer DMDs interact with these barriers to support optimal adherence to therapy.

引用

页码：257 / 266

页数：10

共 73 条

[1] Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis [J].

Alamo, Angela ;

Condorelli, Rosita A. ;

La Vignera, Sandro ;

Calogero, Aldo E. .

INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2019, 33

[2] Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study [J].

Arroyo, Rafael ;

Sempere, Angel P. ;

Ruiz-Beato, Elena ;

Prefasi, Daniel ;

Carreno, Agata ;

Roset, Montse ;

Maurino, Jorge .

BMJ OPEN, 2017, 7 (03)

[3]

Bergmann A, 2014, NEUROLOGY S10, V82

[4] Treatment Patterns in Disease-Modifying Therapy for Patients With Multiple Sclerosis in the United States [J].

Bonafede, Machaon M. ;

Johnson, Barbara H. ;

Wenten, Made ;

Watson, Crystal .

CLINICAL THERAPEUTICS, 2013, 35 (10) :1501-1512

[5] Cladribine tablets' potential role as a key example of selective immune reconstitution therapy in multiple sclerosis [J].

Boyko, Alexey N. ;

Boyko, Olga V. .

DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE, 2018, 8 :35-44

[6] Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study [J].

Calabresi, Peter A. ;

Kieseier, Bernd C. ;

Arnold, Douglas L. ;

Balcer, Laura J. ;

Boyko, Alexey ;

Pelletier, Jean ;

Liu, Shifang ;

Zhu, Ying ;

Seddighzadeh, All ;

Hung, Serena ;

Deykin, Aaron .

LANCET NEUROLOGY, 2014, 13 (07) :657-665

[7] Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations [J].

Canibano, Beatriz ;

Deleu, Dirk ;

Mesraoua, Boulenouar ;

Melikyan, Gayane ;

Ibrahim, Faiza ;

Hanssens, Yolande .

JOURNAL OF DRUG ASSESSMENT, 2020, 9 (01) :20-36

[8] Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments [J].

Clavel, Gaelle ;

Moulignier, Antoine ;

Semerano, Luca .

JOINT BONE SPINE, 2017, 84 (06) :671-675

[9] Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial [J].

Cohen, Jeffrey A. ;

Coles, Alasdair J. ;

Arnold, Douglas L. ;

Confavreux, Christian ;

Fox, Edward J. ;

Hartung, Hans-Peter ;

Havrdova, Eva ;

Selmaj, Krzysztof W. ;

Weiner, Howard L. ;

Fisher, Elizabeth ;

Brinar, Vesna V. ;

Giovannoni, Gavin ;

Stojanovic, Miroslav ;

Ertik, Bella I. ;

Lake, Stephen L. ;

Margolin, David H. ;

Panzara, Michael A. ;

Compston, D. Alastair S. .

LANCET, 2012, 380 (9856) :1819-1828

[10] Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis [J].

Cohen, Jeffrey A. ;

Barkhof, Frederik ;

Comi, Giancarlo ;

Hartung, Hans-Peter ;

Khatri, Bhupendra O. ;

Montalban, Xavier ;

Pelletier, Jean ;

Capra, Ruggero ;

Gallo, Paolo ;

Izquierdo, Guillermo ;

Tiel-Wilck, Klaus ;

de Vera, Ana ;

Jin, James ;

Stites, Tracy ;

Wu, Stacy ;

Aradhye, Shreeram ;

Kappos, Ludwig .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (05) :402-415

← 1 2 3 4 5 6 7 8 →